Trials / Completed
CompletedNCT05532124
Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.
LAENNEC (Human Placenta Hydrolysate) Stiffness of Chronic Liver Disease Patients to Evaluate the Safety and Effectiveness of Multi -Tube, Eye, Placebo, and Capacity Increase and Capacity Enlargement Clinical Trial to Assess the Safety and Effectiveness
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Green Cross Wellbeing · Industry
- Sex
- All
- Age
- 19 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
Part A: In Patients With Chronic Liver Diseases, LAENNEC (Human Placenta Hydrolysate) is to Assess Safety and Tolerability After the Doses of Doses. Part B: Part A, it is to Determine the Optimal Dose by Evaluating Two Capacity and Placebo Groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | LAENNEC (Human Placenta Hydrolysate) | Intravenous Injection |
| OTHER | normal saline | Intravenous Injection |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2023-05-25
- Completion
- 2023-09-27
- First posted
- 2022-09-08
- Last updated
- 2026-02-23
Locations
7 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05532124. Inclusion in this directory is not an endorsement.